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Abstract
Background: Lentiviral vectors have shown immense promise as vehicles for gene delivery to
non-dividing cells particularly to cells of the central nervous system (CNS). Improvements in the
biosafety of viral vectors are paramount as lentiviral vectors move into human clinical trials. This
study investigates the packaging relationship between gene transfer (vector) and Gag-Pol
expression constructs of HIV-1, HIV-2 and SIV. Cross-packaged vectors expressing GFP were
assessed for RNA packaging, viral vector titre and their ability to transduce rat primary glial cell
cultures and human neural stem cells.
Results: HIV-1 Gag-Pol demonstrated the ability to cross package both HIV-2 and SIV gene
transfer vectors. However both HIV-2 and SIV Gag-Pol showed a reduced ability to package HIV-
1 vector RNA with no significant gene transfer to target cells. An unexpected packaging relationship
was found to exist between HIV-2 and SIV with SIV Gag-Pol able to package HIV-2 vector RNA
and transduce dividing SV2T cells and CNS cell cultures with an efficiency equivalent to the
homologous HIV-1 vector however HIV-2 was unable to deliver SIV based vectors.
Conclusion: This new non-reciprocal cross packaging relationship between SIV and HIV-2
provides a novel way of significantly increasing bio-safety with a reduced sequence homology
between the HIV-2 gene transfer vector and the SIV Gag-Pol construct thus ensuring that vector
RNA packaging is unidirectional.
Background
Viral vectors based on primate and non-primate lentivi-
ruses have been shown to be efficient for gene delivery to
a variety of cell types both in vitro and in vivo and may offer
considerable advantages in gene therapy strategies [1,2].
Lentiviral vectors can provide stable gene expression fol-
lowing integration into the host chromosome and pseu-
dotyping of these vectors with heterologous envelopes
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has provided a broad cell tropism [3]. Lentiviral vectors
are particularly suited for transduction of non-dividing
cells [4] such as those of the central nervous system [5]
exemplified by successful therapeutic gene transfer to the
brain of primates for treatment of experimentally induced
Parkinson's disease [6]. Packaging of unspliced vector
mRNA in the producer cell line is a key part in process of
lentiviral vector production and measures to increase the
packaging efficiency and to reduce self packaging of the
Gag-Pol or other helper construct have contributed to
increased vector titre and biosafety [7]. Lentiviral RNA
packaging is achieved by an interaction between an RNA
structure known as the packaging signal or psi and the
nucleocapsid (NC) domain of the Gag structural polypro-
tein. This highly specific process results in the selection of
unspliced viral mRNA from a high background of cellular
mRNA. The packaging signals of several lentiviruses have
been mapped by deletion and mutational analysis. For
HIV-1, sequences between the major splice donor and the
start codon of Gag have been shown to be important for
efficient packaging [8]. HIV-1 may be the exception
amongst lentiviruses since for HIV-2 and SIV, sequences
upstream of the splice donor predominantly contribute to
mRNA packaging [9,10] and in FIV regions in U5 and in
the Gag coding sequence appear to be the major signals
[11,12]. RNA packaging in HIV-2 has been shown to
involve two novel mechanisms to increase specificity,
cotranslational packaging and competition for limiting
Gag polyprotein [13]. These differences in the location of
the major packaging determinants may contribute to the
ability of viral mRNA to be cross packaged by a heterolo-
gous Gag protein. The localisation of RNA capture in the
cell is unclear although recent evidence suggests that the
centrosome may be the primary site [14] and that the psi
signal may act as a subcellular localisatio signal as well as
a high affinity binding site for Gag. The resulting RNA-
protein complex is then targeted to the plasma membrane
where virion budding takes place.
The ability of one lentiviral Gag to cross-package the
unspliced mRNA of another lentivirus species has been
well demonstrated for HIV-1, which can cross-package
HIV-2 [15], SIV [16,17] and FIV [18]. Both SIV and FIV
Gag-Pol have been shown to cross-package HIV-1 mRNA
[16,18], however HIV-2 Gag-Pol is unable to package
HIV-1 mRNA [15]. How closely this reduced efficiency
correlates with the effectiveness of gene transfer of cross-
packaged vectors has not been assessed, in particular in
appropriate primary cells. Cross-packaged lentiviral vec-
tors have been shown to infect predominantly dividing
cells in culture but transduction of neurons and CD34+
lymphocytes has only been shown qualitatively [16].
However chimeric vectors based on an SIV genome and an
HIV-1 core were unable to transduce dendritic cells and
had a reduced ability to transduce primary macrophages
[19].
The production of lentiviral vectors for clinical trials
requires that preparations do not contain replication com-
petent lentiviruses (RCL). Development of PCR and sensi-
tive culture based methods for detection of RCLs have
confirmed the absence of RCLs in large production lots
[20,21]. Production of RCLs can occur through homolo-
gous recombination, thus limiting the sequence similarity
between the Gag-Pol construct and gene transfer vector
will reduce the possibility of a recombination event. Gag-
Pol and gene transfer vectors based on different lentivi-
ruses will significantly reduce the risk of RCL production.
Transduction of the cells of the central nervous system
(CNS), both brain and spinal cord, with lentiviral vectors
has been well documented and long term therapeutic
transgene expression has been reported with only a low
level or transient immune/inflammatory response
[22,23]. Furthermore, transduction of neural stem cells
with lentiviral and adeno associated viral vectors express-
ing therapeutic genes that will affect differentiation and
serve as markers of cell fate is a promising approach for
procuring cells for transplantation into degenerated or
Gag-Pol packaging constructsFigure 1
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to be useful for the treatment of Parkinson's disease, spi-
nal cord injury and other inflammatory or destructive
conditions of the CNS[24,25].
We investigated the cross packaging ability of the Gag-Pol
components of HIV-1, HIV-2 and SIV and found a unique
non-reciprocal packaging relationship between SIV Gag-
pol and vectors based on HIV-2.
In this paper the tropism of these viruses is quantitated by
examining the ability of a series of cross-packaged lentivi-
ral vectors based on HIV-1, HIV-2 and SIV to transduce
primary mixed glial cells which, are the predominant cell
type in the injured brain or spinal cord. Qualitative data is
also presented on the transduction of primary neuronal
embryonic stem cells with cross-packaged vectors.
Results
Cross-Packaging of lentiviral RNA
Following concentration of viral vectors by ultracentrifu-
gation, viral vector particle number was assessed by the
reverse transcriptase assay, which gives a quantitative
measure of RT in ng. The concentration of each viral vec-
tor was normalised to 4 ng/ µl following previous optimi-
sation. The level of vector RNA in the producer cells was
comparable as judged by fluorescence of the cells caused
by expression of the transfected GFP containing vector.
The levels of RNA packaged in virions were assessed by
RT-PCR of the packaged transgene GFP, using specific
primers. Figure 3A and 3B shows a limiting dilution PCR
GFP gene transfer vectorsFigur  2
GFP gene transfer vectors. The dotted line indicates a deletion
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Retrovirology 2005, 2:55 http://www.retrovirology.com/content/2/1/55analysis of virion extracted RNA, reverse transcribed to
cDNA and diluted serially from 1/10 and 1/20 to 1/40.
Electrophoresis of PCR products reveals a limit of positiv-
ity and signal strength. In Figure 3(A) HIV-1 Gag-Pol is
seen to efficiently package HIV-1 RNA and can also cross
package HIV-2 vector RNA at similar levels, both to a lim-
iting dilution of 1/20. In comparison cross packaging of
SIV vector RNA by HIV-1 Gag-Pol is reduced and is similar
to levels of SIV vector RNA packaged by SIV Gag-Pol to
only a limiting dilution of 1/10. In Figure 3(B), SIV Gag-
Pol efficiently cross packages HIV-2 vector RNA to a limit-
ing dilution of 1/40, which is greater than the SIV homol-
ogous vector system (1/10) and the SIV Gag-pol + HIV-
GFP vector system (1/10, data not shown). The ability of
HIV-2 Gag-Pol to cross package HIV-1 and SIV vector RNA
is significantly reduced compared to the homologous
HIV-2 system which showed similar levels of packaged
RNA to the HIV-1 homologous vector system.
Gene transfer efficiency of cross packaged vectors
The semi quantitative PCR approach demonstrates levels
of vector RNA packaged in comparable concentrations of
virions, however the assay does not reflect the gene trans-
fer efficiency of cross-packaged vectors. To address this,
SVC2 cells were transduced with a range of vector-virion
preparations at differing concentrations as measured by
RT-assay. Figure 4 shows a series of FACS plots of GFP pos-
itive cells (lower right quadrant) following transduction
with viral vector and this data is also described in tables
4A to 4C. HIV-1 Gag-Pol was used to package two separate
HIV-1 vectors (+/-cPPT sequence), the gene transfer vector
containing the cPPT demonstrated an increased
Limiting dilution RT PCR of Virion associated GFP RNAFigure 3
Limiting dilution RT PCR of Virion associated GFP RNA. For each viral vector, four PCR s were performed containing a target 
cDNA at neat, 1/10, 1/20 and 1/40 dilution. A: Lanes 1–4, HIV-1 Gag-pol + HIV-1 Vector, Lanes 5–8, HIV-1 Gag-pol + SIV vec-
tor, Lanes 9–12, HIV-1 Gag-pol + HIV-2 vector, Lanes 13–16, SIV Gag-pol + SIV vector. B: Lanes 1–4, SIV Gag-pol + HIV-2 
vector, Lanes 5–8, HIV-2 Gag-pol + HIV-2 vector, Lanes 9–12, HIV-2 Gag-pol + HIV-1 vector, Lanes 13–16, HIV-2 Gag-pol + 
SIV vector.
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Retrovirology 2005, 2:55 http://www.retrovirology.com/content/2/1/55FACS analysis of GFP expression in SV2 cells transduced with homologous and cross-packaged lentiviral vectors (10 ng of vector)igure 4
FACS analysis of GFP expression in SV2 cells transduced with homologous and cross-packaged lentiviral vectors (10 ng of vec-
tor). Lower Right hand quadrant represents GFP positive cells. HIV-1 Gag-Pol + HIV-1GFP vector (A), HIV-1 Gag-Pol + HIV-1 
cPPT-GFP vector (B), HIV-1 Gag-Pol + SIV GFP vector (C), HIV-1 Gag-Pol + HIV-2 GFP vector (D). HIV-2 Gag-Pol + HIV-2 
GFP vector (E), HIV-2 Gag-Pol + SIV GFP vector (F), HIV-2 Gag-Pol + HIV-1 GFP vector (G). SIV Gag-Pol + SIV GFP vector 
(H), SIV Gag-Pol + HIV-2 GFP vector (I), SIV Gag-Pol + HIV-1 GFP vector (J).
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an input viral vector of 10 ng. Transfer of 20 ng of an HIV-
2 vector packaged by HIV-1 Gag-Pol showed a similar
transduction efficiency to that of the HIV-1 cPPT vector
packaged by HIV-1 Gag-Pol, suggesting that the HIV-2
cPPT region also contributed to increased transduction.
Transfer of an SIV vector expressing GFP, cross-packaged
by HIV-1 Gag-Pol was significantly lower, almost six fold,
compared to the homologous HIV-1 viral vector (-cPPT).
It is not certain why this is nor why the homologous SIV
system gave low/poorly reproducible results. Vector
expression appeared comparable in producer cells. SIV
Gag-Pol cross packaged and transferred an HIV-2 GFP vec-
tor at levels slightly higher than the homologous HIV-1
vector system. This is in contrast to the lack of gene trans-
fer of a HIV-1 vector packaged by SIV Gag-Pol. The levels
of HIV-2 vector RNA packaged by SIV Gag-Pol (Figure 3B)
are also reflected in the high gene transfer efficiency. This
packaging relationship between SIV and HIV-2 would
appear to be non-reciprocal, with lower amounts of SIV
vector RNA packaged by the HIV-2 Gag-Pol (Figure 3B)
and no evidence of any significant gene transfer. Compar-
ing the HIV-1 and HIV-2 homologous vector systems
showed that levels of gene transfer to SVC2 cells were
slightly higher for HIV-2 compared to a cPPT negative
HIV-1 vector but lower when compared to the HIV-1 vec-
tor containing the cPPT region. HIV-2 Gag-Pol would
appear to have no ability to cross-package and transfer
HIV-1 vector, which is similar to a previous study [15]
with no significant transduction of SVC2 cells.
One obvious difference between the vectors packaged is
the presence of considerably more potential cis acting
sequence in the HIV-2 based vector compared to the HIV-
1 and SIV vectors. It is conceivable that the presence of
extended cis acting sequence in the gag and pol genes alters
the efficiency of packaging. From data using HIV-1 based
vectors this would seem to be unlikely since the minimal
HIV based vector packages at least as well as a less fully
deleted version. Nevertheless to establish closer compara-
bility we generated a series of further deletions in the HIV-
2 based vector and compared gene transfer efficiency to
that achieved with the minimally deleted vector. The vec-
tor series included one with near complete deletion of the
Gag/Pol coding regions (pSVR∆GP-CMVGFP) and also
the generation of a self inactivating (SIN) vector
(pSVR∆SIN-CMVGFP) created by additional deletion in
the 3' UTR. This will be copied into the 5'LTR during
reverse transcription and thus inactivate the 5'LTR pro-
moter such that expression of the transgene depends on
the internal promoter. The deletion removing the Gag-Pol
region extends into the first coding exons of Tat and Rev
thus both of these vectors will be defective for these regu-
latory proteins and they are closely comparable to the
HIV-1 and SIV vectors used. Using these HIV-2 based con-
a Quantitative assessment of GFP transfer to SVC2 cells by FACS analysis using HIV-1 Gag-Pol to package gene transfer vectors b sed on HIV-1 (+/- cP T sequence), HIV-  and SIVigure 5
a Quantitative assessment of GFP transfer to SVC2 cells by 
FACS analysis using HIV-1 Gag-Pol to package gene transfer 
vectors based on HIV-1 (+/- cPPT sequence), HIV-2 and SIV. 
A range of Viral vector concentrations from 40 ng to 4 ng of 
Reverse Transcriptase was used. (Blank = No data). b Quan-
titative assessment of GFP transfer to SVC2 cells by FACS 
analysis using SIV Gag-Pol to package gene transfer vectors 
based on SIV, HIV-1 and HIV-2. A range of Viral vector con-
centrations from 20 ng to 4 ng of Reverse Transcriptase was 
used. c Quantitative assessment of GFP transfer to SVC2 
cells by FACS analysis using HIV-2 Gag-Pol to package gene 
transfer vectors based on, HIV-2, HIV-2 and SIV. A range of 
Viral vector concentrations from 20 ng to 4 ng of Reverse 
Transcriptase was used.
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Retrovirology 2005, 2:55 http://www.retrovirology.com/content/2/1/55structs we were able to demonstrate no difference in gene
transfer ability with either the more extensively deleted or
the SIN mutated vector. Examples of gene transfer effi-
ciency are shown in Figure 6 in which the level of GFP
expression on transfection and transduction of all of the
HIV-2 vectors is comparable.
Transduction of CNS cell types
We decided to verify this unreported cross-packaging and
gene transfer relationship between SIV Gag-Pol and a HIV-
2 vector by first transducing rat primary mixed glial cul-
tures. The cultures were transduced with either 40 ng or 20
ng of viral vector and the efficiency of transduction com-
pared to that achieved with HIV-1 and HIV-2 homologous
vector systems. Cells were immunostained for GFP expres-
sion and the astrocyte marker GFAP (Figure 7), and
counted (Figure 8). Transducing the glial cultures with 20
ng of a SIV gag-pol+HIV-2 GFP viral vector resulted in GFP
positivity in over 30% cells and approximately 80% of
these positive cells were astrocytes. A similar transduction
rate was seen with the HIV-1 homologous vector system,
which lacks the cPPT sequence using 20 ng of viral vector.
At the same viral vector concentration, the HIV-2 homol-
ogous vector system transduced approximately 25% of
glial cells with 62% of these cells staining for GFAP. The
effect of the cPPT sequence on HIV-1 viral vector transduc-
tion is evident with over 60% of glial cell expressing GFP
with 20 ng of input vector and approximately 58% with
10 ng of vector. In summary, the gene transfer efficiency
of the HIV-2 GFP vector to be cross packaged by SIV Gag-
pol to glial cells was similar to both the HIV-1 and HIV-2
homologous vector systems.
Transduction of human embryonic neuronal stem cells
was also performed using the HIV-1 and HIV-2 homolo-
gous vector system (not shown) and with the SIV Gag-Pol
/HIV-2 GFP. The transduction efficiency was assessed
qualitatively by fluorescence microscopy using 20 ng of
viral vector, and Figure 9 shows that the SIV Gag-pol/HIV-
2 GFP cross packaged vector system transduced both
astrocytes and neurons post differentiation as demon-
strated by immunostaining with GFAP (astrocytes) and
beta-tubulin (neurons). The cross packaged vector system
performed as well as the HIV-1 and HIV-2 homologous
vector systems with astrocytes being transduced at a
slightly higher efficiency.
Discussion
Both lentiviruses and other retroviruses have shown an
ability to cross package other viral genomes with HIV-1
Gag-Pol demonstrating the greatest cross packaging abil-
ity. Non-reciprocal packaging relationships such as have
been demonstrated in HIV-1 and HIV-2 [15] or spleen
necrosis virus and murine leukaemia virus [26] suggest
that individual viruses have different packaging
mechanisms relating possibly to the availability of the
Gag protein or the position of the RNA packaging signal
relative to the major splice donor or other as yet unknown
factors. In this study we demonstrate for the first time a
non-reciprocal packaging relationship between SIV and
HIV-2. Interestingly, the major packaging determinant of
both HIV-2 and SIV has been shown to be upstream of the
major splice donor [9,10] and by inference one would
expect SIV to demonstrate the same co-translational pack-
aging process as HIV-2 [13]. SIV Gag-Pol has been previ-
ously reported to cross package HIV-1 and FIV unspliced
vector mRNA [16,7,18] however the gene transfer ability
of these chimeric vectors has been limited. We could not
demonstrate any appreciable gene transfer of an HIV-1
based vector cross-packaged by SIV Gag-Pol, which is in
contrast to a previous study [16], where transduction of
both dividing and non-dividing cells was demonstrated.
Nor was gene transfer of the HIV-1 GFP seen when pack-
aged by HIV-2 Gag-Pol, in contrast to a previous report
[15].
SIV Gag-Pol packaged similar levels of HIV-1 RNA com-
pared to the homologous SIV vector system (Figure 3A
and 3B), however a significant decrease in gene transfer
was demonstrated with the SIV Gag-Pol/HIV-1 GFP vector
when 4 ng of vector was used to transduce SVC2 cells (Fig-
ure 5B). A similar observation was demonstrated with
HIV-2 Gag-Pol, which packaged equal levels of HIV-1 GFP
and SIV GFP vector RNA and showed no appreciable gene
transfer with 4 ng of vector. The RT-PCR data on virion
extracted RNA suggests that low levels of RNA are being
packaged. Why this does not translate into detectable gene
transfer is not clear although the RT-PCR does not reveal
whether complete or damaged genomes are being pack-
aged. Gene transfer may be a threshold phenomenon in
which many virions contain defective genomes and only
a few have a full genomic RNA. Alternatively there may be
an additional block in functional gene transfer either at
reverse transcription or integration. Indeed, there is no
reported data on the function of SIV reverse transcriptase
or integrase in an HIV-1 backbone. The cross packaging
ability of HIV-1 Gag-Pol was demonstrated by its ability to
package both HIV-2 and SIV RNA and effect GFP gene
transfer. HIV-1 Gag-Pol packaged a greater level of HIV-2
RNA than SIV RNA and a significantly greater number of
cells were transduced with the HIV-1 Gag-Pol/HIV-2 GFP
vector.
One advantage of a chimeric lentiviral vector is a reduc-
tion in the risk of development of a replication competent
retrovirus which may occur through a recombination
event due to sequence homology between the Gag-Pol
and gene transfer constructs. However it is important to
assess the gene transfer capabilities of these chimeric vec-
tors in suitable primary cells. This has been highlighted inPage 7 of 14
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Retrovirology 2005, 2:55 http://www.retrovirology.com/content/2/1/55GFP expression from HIV-2 vectors following transfection inot produced cells and in cells transduced with the packaged vectorsFigure 6
GFP expression from HIV-2 vectors following transfection inot produced cells and in cells transduced with the packaged 
vectors.
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packaged by HIV-1 Gag-Pol showed a reduced transduc-
tion efficiency of human dendritic cells associated with a
post-entry defect. [19]. A second major advantage of this
chimeric system is the ability to deliver a cross-packaged
vector to a simian animal model with a vector based on
SIV Gag-Pol packaging an HIV-2 genome. The same com-
bination could subsequently be used in humans allowing
biosafety and bio-distribution studies to be performed
directly without the necessity for surrogate systems. This is
not possible with an HIV-1 based system and would give
the SIV/HIV-2 system considerable advantages over other
primate lentiviral combinations.
Rat astrocytes are the major cell type associated with the
glial scar resulting from injury to the CNS [27] and human
fetal embryonic neural stem cells offer the potential for
regenerating damaged areas of the CNS [28]. Engraftment
of neural stem cells transduced with a lentiviral vector
based on HIV-1 has been demonstrated with a high level
and duration of transgene expression[29]. Our results
demonstrate that both the HIV-1 and HIV-2 homologous
GFP lentivectors efficiently transduced rat primary astro-
cytes. Similar to previous studies on the effect of the cPPT
sequence on gene transfer [30,31] our data shows that the
presence of the cPPT sequence in the HIV-1 vector results
in a two fold increase in transduction efficiency, similar to
the HIV-2 homologous vector system which also contains
the HIV-2 cPPT in the pol sequence. The SIV Gag-Pol/ HIV-
2 GFP vector also transduced primary astrocytes with effi-
ciency similar to the HIV-1 cPPT homologous vector
system, indicating no associated post-entry defects. Effi-
cient transduction of human fetal embryonic neural stem
cells was also shown with the cross packaged SIV Gag-Pol/
HIV-2 GFP vector highlighting the ability of this vector to
transduce human cells.
Conclusion
We have identified a non reciprocal cross packaging rela-
tionship between SIV Gag-Pol and a HIV-2 based GFP vec-
tor, which demonstrated equivalent transduction
efficiencies in 293T cells, rat primary astrocytes and
embryonic stem cells as that of homologous HIV-1 and
HIV-2 vector systems. The efficiency of the combination
correlates with the level of vector RNA packaged indicat-
ing that this is a major determinant of vector efficiency. It
suggests that there are as yet unidentified differences in
the RNA capture mechanisms of HIV-1, HIV-2 and SIV.
The implications for testing of lentiviral vector biosafety
are potentially very important. Testing in appropriate ani-
mal models is a major concern associated with the use of
Transduction of rat mixed glial cells with a HIV-2 based lentiviral vector packaged by SIV gag-polFigure 7
Transduction of rat mixed glial cells with a HIV-2 based lentiviral vector packaged by SIV gag-pol. (A) GFP expression in len-
tivector transduced cells. (B) GFAP co-staining of astrocytes.
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Retrovirology 2005, 2:55 http://www.retrovirology.com/content/2/1/55lentiviral vectors in clinical trials. As HIV-1 only causes
AIDS in humans, there is presently no animal model to
test the safety of HIV-1 based vectors. However animal
models based on Asian macaques and baboons exist for
SIV and HIV-2, respectively which may be applicable to
testing the biosafety of SIV cross packaged HIV-2 lentiviral
vectors.
Methods
Lentiviral vectors
The lentiviral gene transfer vectors and Gag-Pol expression
constructs are outlined in Figures 1 and 2. The constructs
based on HIV-1 and SIV have been previously described
[4,32] and were kind gifts of D. Trono and K. Uberla. The
HIV-1 gene transfer vector HR'GFP was modified to
Transduction of Rat primary mixed glial cultures with Lentiviral vectors based on HIV-1 packaged by HIV-1 Gag-pol(A), HIV-1 +cPPT vector packaged by HIV-1 Gag-pol (B), HIV-2 vector p ckaged by SIV Gag-pol (C) nd HIV-2 vector packaged by 2Gag-pol (D)Figure 8
Transduction of Rat primary mixed glial cultures with Lentiviral vectors based on HIV-1 packaged by HIV-1 Gag-pol(A), HIV-1 
+cPPT vector packaged by HIV-1 Gag-pol (B), HIV-2 vector packaged by SIV Gag-pol (C) and HIV-2 vector packaged by HIV-2 
Gag-pol (D). Error bars indicate within experimental SEM.
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flap sequence. The sequence was PCR amplified and
cloned into the unique Cla1 site upstream of the Rev
Responsive Element (RRE) sequence using cPPT primer
sequences described [30]. The HIV-2 gene transfer vector
was also modified from the construct pSVR∆NBPuro∆H
[13] by replacing the SV40-Puromycin construct with a
CMV-GFP reporter gene construct to create pSVR∆-
CMVGFP. The HIV-2 Gag-Pol construct, (pSVR∆NBDM)
contains a deletion in the 5'untranslated region, which
has been shown to abrogate packaging [13].
Construction of minimal HIV-2 based vectors
pSVR∆NB∆H [13] was digested with BsmBI, and a ClaI
linker was inserted into the site. ClaI and EcoRV digestion
of this produced two DNA fragments, the smaller of
which (nucleotides 1101–6128 encompassing gag and pol
sequences) was discarded. The remaining fragment was
religated and formed pSVR∆GP. CMVGFP was obtained
from SalI digestion of pSVR∆-CMVGFP and ligated into
the SalI linker of dephosphorylated pSVR∆GP to give
pSVR∆GP-CMVGFP.
Transduction of neural stem cells by a HIV-2 based GFP lentiviral vector packaged by SIV-2 Gag-PolFigure 9
Transduction of neural stem cells by a HIV-2 based GFP lentiviral vector packaged by SIV-2 Gag-Pol. (A) Phase contrast image 
through growing neurosphere (upper left). (B) Fluorescent image of neurosphere in A expressing GFP 72 hours post transduc-
tion (upper right). (C) Confocal image through neurosphere expressing GFP (lower left) (D) Neurons derived from human 
neurosphere 7 days post differentiation (lower right). Red represents β tubulin III, green – GFP, Hoechst stain (blue) nuclei. 
Arrow denotes double labelled cell. Magnification in A and B = 10×, in C = 100×, D = 40×
BA
C DPage 11 of 14
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regions, and Sp1, κB and peri-κB binding sites that are
responsible for transcription from the 5'LTR. This 141 bp
region (nucleotides 9329–9470) was deleted in the 3'LTR
to produce a SIN vector as follows. The 3'LTR was
removed from pSVR∆GP, by BamHI and XbaI digestion,
and subcloned into pBluescript II KS. Site directed muta-
genesis introduced BglII restriction sites at the 5' and 3'
ends of the 141 bp region that was to be deleted. Mutagen-
esis was carried out as in two stages using the following
primers: stage 1, upstream mutagenesis:- 5'-
GGAATACCATTTAGTTAAAGATCTGAACAGCTATACTT-
GGTCAGGG-3' and :- 5'-CCCTGA
CCAAGTATAGCTGTTCAGATCTTTAACTAAATGGTATTC
C-3'; for stage 2, downstream mutagenesis, 5'-
CGCCCTCATATTCTCTGTATAGATCTACCCGCTAGCTT-
GCATTG-3' and 5'-CAATGCAAGCTAGCGGGTAGATC-
TATACAGAGAATATGAGGGCG-3'.
The 141 bp U3 region was removed from the plasmid by
BglII digestion and the plasmid religated. BamHI and XbaI
digestion of the plasmid and religation of the ∆3'LTR into
pSVR∆GP created the pSVR∆SIN vector. CMVGFP was
inserted as described to produce the vector pSVR∆SIN-
GFP
Lentiviral vector production
Lentiviral vectors were produced by calcium phosphate
transfection of 293T cells grown in DMEM media and
10% FCS with 7 µg of the gene transfer vector, 7 µg of the
Gag-Pol construct, 3 µg of a Rev expressor and 3 µg of the
VSV-G heterologous envelope. For HIV-2 and SIV vector
production the Rev expressor was omitted. 24 hours fol-
lowing transfection the media was replaced and superna-
tant containing recombinant virions was recovered 48
hours post transfection. Virions were concentrated by
ultracentrifugation for 2.5 hours at 25,000 RPM in an
SW28 Beckmann rotor. The viral pellet was resuspended
in 300 µl of tissue culture media, aliquoted and stored at
-70°C.
Lentiviral vectors were quantitated using a commercially
available RT-assay (Cavid Tech, Uppsala) Vector prepara-
tions were measured in duplicate and normalised to a
concentration of 8 ng of RT per µl. Although the sensitiv-
ity of the assay for different RTs may be slightly different
the fact that each Gag-Pol construct is being used to pack-
age each vector provides an internal control.
Levels of RNA packaging were assessed by RT-PCR of Vir-
ion associated RNA. Virion RNA was extracted using the
Qiagen Viramp kit from 10 ng of virus (RT levels). Follow-
ing extraction the RNA was also treated with RNase Free
DNase for 10 mins at 37°C and the DNase was in acti-
vated by incubation at 70°C for a further 10 mins. An
aliquot of RNA was reverse transcribed to cDNA using the
Promega Improm RT system with an antisense GFP
primer (AAGTCGTGCTGCTTCATGTG). The cDNA was
then serially diluted and amplified using a sense primer
(GACGTAAACGGCCACAAGTT) and the antisense
primer. Amplified products were resolved by agarose gel
electrophoresis and EtBR staining.
The transduction efficiency of cross-packaged vectors was
assessed by FACS analysis of GFP positive cells. A range of
viral vector concentration from 40 ng to 4 ng was used to
transduce 1 × 106 of fibroblast SV2C cells in a six well
plate. Viral vector was diluted in DMEM containing 6 µg/
ml polybrene and cells were exposed to virus for 5 hours.
The media was then replaced and GFP expression was
assessed at time periods after 72 hours post transduction.
Glial cell Culture and Stem cell culture
Primary mixed glial cultures were prepared from the
brains of newborn rats > 3 days old by dissociation of
whole cortex in trypsin, then cultured in poly-D-lysine
coated flasks in DMEM/10% FCS. Mixed glial cultures
were derived from these cells, once they were confluent,
by trypsinisation. The cells were then resuspended in
DMEM containing 10% FCS and 1% PSF and centrifuged
at 10,000 RPM for 5 minutes. The supernatant was
removed and cells were resuspended in DMEM/10% FCS
and plated onto Poly-D-Lysine coated coverslips in 24
well plates. Transduction of glial cultures with lentiviral
vectors was carried out as described for SV2C cultures. 72
hours post transduction; glial cultures were fixed in 4%
paraformaldehyde and stored in PBS at 4°C prior to
immunostaining.
Human fetal neuronal stem cell culture was performed as
described previously [33]. Transduction of Stem cell cul-
tures of cortical origin was performed with 20 ng of viral
vector in DMEM/ HAMS F12 (2:1), 1% N2, EGF (20 ng/
ml) FGF-2 (20 ng/ml) and heparin (5 mg/ml) for four
hours followed by replacement of the media. Cells were
allowed to differentiate on poly-L-lysine/laminin coated
coverslips followed by replacement of the media 72 hours
post transduction. Cells were fixed in 4%
paraformaldehyde after a further 96 hours, followed by
immunostaining for GFP, GFAP and β-Tubulin III.
Immunostaining
Lentiviral vector transduced mixed glial cultures were first
blocked using 3% goat serum in TXTBS (0.2% triton X-
100, in Tris Buffered Saline) for one hour. Monoclonal
anti GFAP (Sigma, 1:500) and polyclonal goat anti rabbit
GFP (Molecular Probes), 1: 1000) were diluted in TXTBS
with 1% normal goat serum (NGS) for 2 hours. Cells were
then washed in TBS for 3 × 10 minutes. Cells were then
incubated with secondary antibodies, goat anti mousePage 12 of 14
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Retrovirology 2005, 2:55 http://www.retrovirology.com/content/2/1/55Alexa (Molecular Probes, 1:500) and biotinylated goat
anti rabbit (Amersham Biosciences, 1:500) for 90
minutes. Following a second 3 × 10 minute wash in TBS,
Streptavidin-FITC (Serotec, 1:100) was added in TBS with
1% NGS and Bis-benzamide (Sigma, 1:5000). Coverslips
were then mounted in Fluorosave reagent (Calbiochem).
Cell counts of immunostained mixed glial cultures were
performed from one edge of the coverslip all the way
across to the other, horizontally and vertically. A 0.5 mm2
area was counted every 1.5 mm.
Competing interests
PS, DB and AML are inventors on various patents filed by
the University of Cambridge containing usage claims for
chimeric lentiviral vectors. There are no licences currently
associated with these patents.
Authors' contributions
PS, AML and JWF jointly conceived of these studies. PS
produced and titered the lentiviral vectors, performed
FACS analysis and RT-PCR analysis and transduced cell
lines, primary glial cells and neural stem cells. DWH pro-
duced the primary mixed glial cultures. DB cloned the
CMV-GFP cassette into the HIV-2 vector and performed
the comparative analysis of the HIV-2 vectors. BCG cloned
the HIV-1 cPPT region into the HIV-1 vector. MC pro-
duced the neural stem cell cultures. PS drafted this manu-
script, which was critically reviewed by AML and JWF.
Acknowledgements
This work was supported by a programme grant from the Medical Research 
Council (UK)
References
1. Trono D: Lentiviral vectors: turning a deadly foe into a ther-
apeutic agent.  Gene Therapy 2000, 7:20-23.
2. Connolly JB: Lentiviruses in gene therapy clinical research.
Gene Therapy 2002, 9:1730-1734.
3. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply atten-
uated lentiviral vector achieves efficient gene delivery in
vivo.  Nat Biotechnol 1997:871-875.
4. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM,
Trono D: In vivo gene delivery and stable transduction of non-
dividing cells by a lentiviral vector.  Science 1996, 272:263-267.
5. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH: Highly
efficient and sustained gene transfer in adult neurons with a
lentivirus vector.  J Virol 1997, 71:6641-6649.
6. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L,
McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE,
Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon
N, Aebischer P: Neurodegeneration prevented by lentiviral
vector delivery of GDNF in primate models of Parkinson's
disease.  Science 2000, 290:767-773.
7. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini
L: A third generation lentivirus vetor with a conditional pack-
aging system.  J Virol 1998, 72:8463-8471.
8. Lever A, Gottlinger H, Haseltine W, Sodroski J: Identification of a
sequence required for efficient packaging of human immun-
odeficiency virus type 1 RNA into virions.  J Virol 1989,
63:4085-4087.
9. McCann EM, Lever AM: Location of cis-acting signals important
for RNA encapsidation in the leader sequence of human
immunodeficiency virus type 2.  J Virol 1997, 71:4133-4137.
10. Strappe PM, Greatorex J, Thomas J, Biswas P, McCann E, Lever AM:
The packaging signal of simian immunodeficiency virus is
upstream of the major splice donor at a distance from the
RNA cap site similar to that of human immunodeficiency
virus types 1 and 2.  J Gen Virol 2003, 84:2423-2430.
11. Kemler I, Barraza R, Poeschla EM: Mapping the encapsidation
determinants of feline immunodeficiency virus.  J Virol 2002,
76:11889-11903.
12. Browning MT, Mustafa F, Schmidt RD, Lew KA, Rizvi TA: Delinea-
tion of sequences important for efficient packaging of feline
immunodeficiency virus RNA.  J Gen Virol 2003, 84:621-627.
13. Griffin SD, Allen JF, Lever AM: The major human immunodefi-
ciency virus type 2 (HIV-2) packaging signal is present on all
HIV-2 RNA species: Cotranslational RNA encapsidation and
limitation of Gag protein confer specificity.  J Virol 2001,
75:12058-12069.
14. Poole E, Strappe P, Mok HP, Hicks R, Lever AM: HIV-1 Gag-RNA
interaction occurs at a perinuclear/centrosomal site; analysis
by confocal microscopy and FRET.  Traffic 2005. in press
15. Kaye JF, Lever AML: Nonreciprocal packaging of human immu-
nodeficiency virus type 1 and type 2 RNA: a possible role for
the p2 domain of Gag in RNA encapsidation.  J Virol 1998,
72:5877-5885.
16. White SM, Renda M, Nam NY, Klimatcheva E, Zhu Y, Fisk J, Halter-
man M, Rimel BJ, Federoff H, Pandya S, Rosenblatt JD, Planelles V:
Lentivirus vectors using human and simian immunodefi-
ciency virus elements.  J Virol 1999, 73:2832-2840.
17. Rizvi TA, Panganiban AT: Simian immunodeficiency virus RNA
is efficiency encapsidated by human immunodeficiency virus
type 1 particles.  J Virol 1993, 67:2681-2688.
18. Browning MT, Schmidt RD, Lew KA, Rizvi TA: Primate and Feline
lentivirus vector RNA packaging and propagation by heter-
ologous lentivirus virions.  J Virol 2001, 75:5129-5140.
19. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cima-
relli A: Heterologous human immunodeficiency virus type 1
lentiviral vectors packaging a simian immunodeficiency virus
derived genome display a specific postentry transduction
defect in dendritic cells.  J Virol 2003, 77:9295-9340.
20. Sastry L, Xu Y, Johnson T, Desai K, Rissing D, Marsh J, Cornetta K:
Certification assays for HIV-1-based vectors: frequent pas-
sage of gag sequences without evidence of replication-com-
petent viruses.  Mol Ther 2003, 8:830-839.
21. Escarpe P, Zayek N, Chin P, Borellini F, Zufferey R, Veres G, Kiermer
V: Development of a sensitive assay for detection of replica-
tion-competent recombinant lentivirus in large-scale HIV-
based vector preparations.  Mol Ther 2003, 8:332-341.
22. Zhao C, Strappe PM, Lever AM, Franklin RJ: Lentiviral vectors for
gene delivery to normal and demyelinated white matter.  Glia
2003, 42:59-67.
23. Baekelandt V, Eggermont K, Michiels M, Nuttin B, Debyser Z: Opti-
mized lentiviral vector production and purification proce-
dure prevents immune response after transduction of
mouse brain.  Gene Ther 2003, 10:1933-1940.
24. Ruitenberg MJ, Blits B, Dijkhuizen PA, Beek ET, Bakker A, van
Heerikhuize JJ, Pool CW, Hermens WT, Boer GJ, Verhaagen J:
Adeno-associated viral vector-mediated gene transfer of
brain-derived neurotrophic factor reverses atrophy of rubro-
spinal neurons following both acute and chronic spinal cord
injury.  Neurobiol Dis 2004, 15:394-406.
25. Ostenfeld T, Tai YT, Martin P, Deglon N, Aebischer P, Svendsen :
Neurospheres modified to produce glial cell line-derived
neurotrophic factor increase the survival of transplanted
dopamine neurons.  J Neurosci Res 2002, 69:955-965.
26. Certo JL, Shook BF, Yin PD, Snider JT, Hu WS: Nonreciprocal
pseudotyping: murine leukaemia virus proteins cannot effi-
ciently package spleen necrosis virus based vector RNA.  J
Virol 1998, 72:5408-5413.
27. Properzi F, Fawcett JW: Proteoglycans and brain repair.  News
physiol Sci 2004, 19:33-38.
28. Tai YT, Svendsen CN: Stem cells as a potential treatment of
neurological disorders.  Curr Opin Pharmacol 2004, 4:98-104.
29. Englund U, Ericson C, Rosenblad C, Mandel RJ, Trono D, Wictorin K,
Lundberg C: The use of a recombinant lentiviral vector for ex
vivo gene transfer into the rat CNS.  Neuroreport 2000,
11:3973-3977.Page 13 of 14
(page number not for citation purposes)
Retrovirology 2005, 2:55 http://www.retrovirology.com/content/2/1/55Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
30. Manganini M, Serafini M, Banbacioni F, Casati C, Erba E, Follenzi A,
Naldini L, Bernasconi S, Gaipa G, Rambaldi A, Biondi A, Golay J, Int-
rona M: A human immunodeficiency virus type 1 pol gene-
derived sequence (cPPT/CTS) increases the efficiency of
transduction of human nondividing monocytes and T lym-
phocytes by lentiviral vectors.  Hum Gene Ther 2002,
13:1793-1807.
31. Zennou V, Serguera C, Sarkis C, Colin P, Perret E, Mallet J, Charneau
P: The HIV-1 DNA flap stimulates HIV vector-mediated cell
transduction in the brain.  Nat Biotechnol 2001, 5:446-450.
32. Schnell T, Foley P, Wirth M, Munch J, Uberla K: Development of a
self-inactivating, minimal lentivirus vector based on simian
immunodeficiency virus.  Hum Gene Ther 2000, 11:439-447.
33. Svendsen CN, ter Borg MG, Armstrong RJ, Rosser AE, Chandran S,
Ostenfeld T, Caldwell MA: A new method for the rapid and long
term growth of human neural precursor cells.  J Neurosci Meth
1998, 85:141-152.Page 14 of 14
(page number not for citation purposes)
